Drugs & Aging

, Volume 32, Issue 7, pp 515–524 | Cite as

Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations

  • Éric ToussirotEmail author
Leading Article


Spondyloarthritis (SpA) is usually observed in young patients while onset in the elderly is less common. Late-onset forms of SpA may become more common due to longer life expectancy. The clinical spectrum of late-onset SpA is as broad as in young people, with a predominance of peripheral SpA over pure axial disease. The Assessment of SpondyloArthritis international Society (ASAS) has developed new criteria for axial or peripheral SpA that allow patients aged under 45 years at the time of disease onset to be identified. These criteria are not theoretically adapted for the classification of patients with late-onset disease but they are useful for the diagnosis. Similarly, magnetic resonance imaging (MRI) is now widely used for the early recognition of sacroiliitis or spinal inflammation in SpA, and sacroiliitis as evidenced by MRI is included in the ASAS criteria for axial SpA. Nevertheless, the utility of sacroiliac joint and/or spine inflammation as detected by MRI has mostly been described in young patients with ankylosing spondylitis, SpA, or inflammatory back pain, but not in the elderly. The management of SpA is now more focused on remission or, alternatively, low disease activity, according to the treat-to-target recommendations. Such an optimized approach to therapy is thought to improve patient outcomes and ultimately long-term quality of life. The same principles of treatment should apply in the elderly, but require certain adjustments, especially with biological agents. Tumor necrosis factor-α blocking agents are very effective in SpA, but seem slightly less effective in the elderly and are associated with an increased risk of infection in this population. A careful and rigorous evaluation is thus required before initiating these agents in elderly subjects.


Ankylose Spondylitis Bone Marrow Edema Bath Ankylose Spondylitis Disease Activity Index Ustekinumab Spinal Magnetic Resonance Imaging 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards

Conflict of interest & Funding

The author has no conflicts of interest that are directly relevant to the content of this article. No funding was received for the preparation of the manuscript.


  1. 1.
    Dougados M, Baten D. Spondyloarthritis. Lancet. 2011;377:2127–37.PubMedCrossRefGoogle Scholar
  2. 2.
    Braun J, Sieper J. Classification, diagnosis, and referral of patients with axial spondyloarthritis. Rheum Dis Clin North Am. 2012;38:477–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Olivieri I, D’Angelo S, Padula A, et al. Spondyloarthritis with onset after age 45. Curr Rheumatol Rep. 2013;15:374.PubMedCrossRefGoogle Scholar
  4. 4.
    Toussirot E, Wendling D. Late onset ankylosing spondylitis and related spondylarthropathies. Clinical and radiological characteristics and pharmacological treatment options. Drugs Aging. 2005;22:451–69.PubMedCrossRefGoogle Scholar
  5. 5.
    Rudwaleit M, Van der Heijde DM, Landewé R, et al. The development of Assessment of Spondylarthritis international Society classification criteria for axial spondylarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;69:777–83.CrossRefGoogle Scholar
  6. 6.
    Rudwaleit M, van der Heijde DM, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Weber U, Maksymowych WP. Advances and challenges in spondyloarthritis imaging for diagnosis and assessment of disease. Curr Rheumatol Rep. 2013;15:345.PubMedCrossRefGoogle Scholar
  8. 8.
    Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs. 1998;56:225–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Sieper J. Developments in therapies for spondyloarthritis. Nat Rev Rheumatol. 2012;8:280–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6–16.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Toussirot E. Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies. Drugs Aging. 2010;27:523–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Dubost JJ, Sauvezie B. Late onset peripheral spondylarthropathy. J Rheumatol. 1989;16:1214–7.PubMedGoogle Scholar
  13. 13.
    Caplanne D, Tubach F, Le Parc JM. Late onset spondylarthropathy: clinical and biological comparison with early onset patients. Ann Rheum Dis. 1997;56:176–9.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Olivieri I, Padula A, Pierro A, et al. Late onset seronegative spondylarthopathy. J Rheumatol. 1995;22:899–903.PubMedGoogle Scholar
  15. 15.
    Punzi L, Pianon M, Rossini P, et al. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis. 1999;58:226–9.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Olivieri I, Pipitone N, D’Angelo S, et al. Late onset rheumatoid arthritis and late onset spondylarthritis. Clin Exp Rheumatol. 2009;27(Suppl 55):S139–45.PubMedGoogle Scholar
  17. 17.
    Skare TL, Leite N, Bortoluzzo AB, et al. Effect of age at disease onset in the clinical profile of spondyloarthritis: a study of 1424 Brazilian patients. Clin Exp Rheumatol. 2012;30:351–7.PubMedGoogle Scholar
  18. 18.
    Montilla C, Del Pino-Montes J, Collantes-Estevez E, et al. Clinical features of late-onset ankylosing spondylitis: comparison with early-onset disease. J Rheumatol. 2012;39:1008–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Chen HA, Chen CH, Liao HT, et al. Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. J Rheumatol. 2012;39:1013–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36:361–7.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Eder L, Chandran V, Shen H, et al. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken). 2011;63:619–22.PubMedCrossRefGoogle Scholar
  22. 22.
    van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Helliwell PS, Porter G, Taylor WJ, CASPAR Study Group. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis. 2007;66:113–7.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    D’Angelo S, Gilio M, Palazzi C, et al. Clinical and laboratory features of late-onset psoriatic arthritis in comparison with younger-onset disease: data from an early arthritis cohort. Ann Rheum Dis. 2013;72(Suppl 3):686.CrossRefGoogle Scholar
  25. 25.
    Weber U, Lambert RG, Østergaard M, et al. The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum. 2010;62:3048–58.PubMedCrossRefGoogle Scholar
  26. 26.
    Bennett AN, Rehman A, Hensor EM, et al. Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. Arthritis Rheum. 2009;60:1331–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Weber U, Hodler J, Kubik RA, et al. Sensitivity and specificity of spinal inflammatory lesions assessed by whole-body magnetic resonance imaging in patients with ankylosing spondylitis or recent onset inflammatory back pain. Arthritis Rheum. 2009;61:900–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging for classification of axial spondylarthritis: a consensual approach by ASAS/OMERACT MRI group. Ann Rheum Dis. 2009;68:1520–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Hermann KG, Baraliakos X, van der Heijde DM, et al. Assessment in SpondyloArthritis international Society (ASAS). Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis. 2012;71:1278–88.PubMedCrossRefGoogle Scholar
  30. 30.
    Shankaranarayana S, Tan AL, Madden J, et al. Fat-suppression magnetic resonance imaging in the diagnosis of late-onset axial spondyloarthropathy. Ann Rheum Dis. 2007;66:1405–6.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Shibata Y, Shirai Y, Miyamoto M. The aging process in the sacroiliac joint: helical computed tomography analysis. J Orthop Sci. 2002;7:12–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Herrmann J, Krstin N, Schoennagel BP, et al. Age-related distribution of vertebral bone-marrow diffusivity. Eur J Radiol. 2012;8:4046–9.CrossRefGoogle Scholar
  33. 33.
    D’Agostino MA, Aegerter P, Bechara K, et al. How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography. Ann Rheum Dis. 2011;70:1433–40.PubMedCrossRefGoogle Scholar
  34. 34.
    Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381–90.PubMedCrossRefGoogle Scholar
  36. 36.
    Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73:238–42.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Anderson JJ, Baron G, Van Der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876–86.PubMedCrossRefGoogle Scholar
  38. 38.
    Lukas C, Landewé R, Sieper J, et al. Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18–24.PubMedCrossRefGoogle Scholar
  39. 39.
    Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986–91.PubMedCrossRefGoogle Scholar
  40. 40.
    Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387–94.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Coates LC, Navarro-Coy N, Brown SR, et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord. 2013;14:101.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Coates LC, Moverley A, McPArland L, et al. Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control imorve outcome. Arthritis Rheum. 2013;65(suppl):S346.Google Scholar
  43. 43.
    Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002;359:1187–93.PubMedCrossRefGoogle Scholar
  44. 44.
    Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. A randomized, controlled trial. Arthritis Rheum. 2003;48:3230–6.PubMedCrossRefGoogle Scholar
  45. 45.
    der Heijde Van, Kivitz A, Schiff M, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–46.PubMedCrossRefGoogle Scholar
  46. 46.
    Inman RD, Davis JC, Van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis. Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402–12.PubMedCrossRefGoogle Scholar
  47. 47.
    Landewe R, Barun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double blind randomised placebo controlled phase 3 study. Ann Rheum Dis. 2014;73:39–47.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non –radiographic axial spondyloarthritis: results of a randomized placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815–22.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Dougados M, Van der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiogarphic axial spondyloarthritis. A multicentre, randomised, double blind, placebo controlled trial. Arthritis Rheumatol. 2014;66:2091–102.PubMedCrossRefGoogle Scholar
  50. 50.
    Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–90.PubMedCrossRefGoogle Scholar
  51. 51.
    Antoni C, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227–36.PubMedCrossRefGoogle Scholar
  52. 52.
    Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476–88.PubMedCrossRefGoogle Scholar
  53. 53.
    Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64:2504–17.PubMedCrossRefGoogle Scholar
  54. 54.
    Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48–55.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Baraliakos X, van den Berg R, Braun J, et al. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology. 2012;51:1378–87.PubMedCrossRefGoogle Scholar
  56. 56.
    Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4–12.PubMedCrossRefGoogle Scholar
  57. 57.
    Lahaye C, Tatar Z, Dubost JJ, et al. Overview of biologic treatments in the elderly. Jt Bone Spine. 2015;82:154–60.CrossRefGoogle Scholar
  58. 58.
    Radovits BJ, Kievit W. Laan RFJM. Tumour necrosis factor α antagonists in the management of rheumatoid arthritis in the elderly. A review of their efficacy and safety. Drugs Aging. 2009;26:647–64.PubMedCrossRefGoogle Scholar
  59. 59.
    Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65:1226–9.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Kawai VK, Grijalva CG, Arbogast PG, et al. Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63:1415–24.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379–84.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Fleischmann R, Iqbal I. Risk/benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007;24:239–54.PubMedCrossRefGoogle Scholar
  63. 63.
    Schneeweiss S, Setoguchi S, Weinblatt L, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754–64.PubMedCrossRefGoogle Scholar
  64. 64.
    Genevay S, Finchk A, Ciurea A, et al. Tolerance and effectiveness of anti-tumor necrosis factor a therapies in elderly patients with rheumatoid arthritis: a population based cohort study. Arthritis Rheum. 2007;57:679–85.PubMedCrossRefGoogle Scholar
  65. 65.
    Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1470–3.PubMedCrossRefGoogle Scholar
  66. 66.
    Fillipini M, Bazzani C, Favalli EG, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38:90–6.CrossRefGoogle Scholar
  67. 67.
    Ornetti P, Chevillotte H, Zerrak A, et al. Anti-tumour necrosis factor-alpha therapy for rheumatoid arthritis and other inflammatory arthropathies: update on safety in older patients. Drugs Aging. 2006;23:855–60.PubMedCrossRefGoogle Scholar
  68. 68.
    Tran S, Hooker RS, Cipher DJ, et al. Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post marketing study. Drugs Aging. 2009;26:607–15.PubMedCrossRefGoogle Scholar
  69. 69.
    Migliore A, Bizzi E, Lagana B, et al. The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol. 2009;22:415–26.PubMedGoogle Scholar
  70. 70.
    Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology. 2005;44:695–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11:159–68.PubMedCrossRefGoogle Scholar
  72. 72.
    Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990–9.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–13.PubMedCrossRefGoogle Scholar
  74. 74.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–6.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Diaz-Borjon A. Guidelines for the use of conventional and newer disease modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging. 2009;26:273–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Clinical Investigation Center in Biotherapy, INSERM CIC-1431University Hospital of BesançonBesançonFrance
  2. 2.FHU INCREASE, University Hospital of BesançonBesançonFrance
  3. 3.Department of RheumatologyUniversity Hospital of BesançonBesançonFrance
  4. 4.Department of Therapeutics and EA 4266 “Pathogens and Inflammation”, SFR FED 4234University of Franche-ComtéBesançonFrance

Personalised recommendations